105.64
price up icon0.29%   0.125
 
loading
Abbott Laboratories stock is traded at $105.64, with a volume of 2.01M. It is up +0.29% in the last 24 hours and down -1.84% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$105.52
Open:
$105.69
24h Volume:
2.01M
Relative Volume:
0.18
Market Cap:
$182.76B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
34.15
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
-4.20%
1M Performance:
-1.84%
6M Performance:
-6.05%
1Y Performance:
-19.80%
1-Day Range:
Value
$104.78
$106.86
1-Week Range:
Value
$104.78
$112.00
52-Week Range:
Value
$81.97
$137.49

Abbott Laboratories Stock (ABT) Company Profile

Name
Name
Abbott Laboratories
Name
Phone
(224) 667-6100
Name
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
Employee
115,000
Name
Twitter
@AbbottNews
Name
Next Earnings Date
2026-10-21
Name
Latest SEC Filings
Name
ABT's Discussions on Twitter

Compare ABT vs MDT, SYK, BSX, EW

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ABT icon
ABT
Abbott Laboratories
105.62 182.59B 46.59B 5.41B 7.38B 3.0938
MDT icon
MDT
Medtronic Plc
92.38 118.18B 36.36B 4.84B 5.43B 3.7261
SYK icon
SYK
Stryker Corp
272.54 106.03B 25.27B 3.34B 4.57B 8.6334
BSX icon
BSX
Boston Scientific Corp
45.12 65.19B 20.62B 3.56B 3.48B 2.3847
EW icon
EW
Edwards Lifesciences Corp
86.08 49.99B 6.30B 1.07B 1.09B 1.8406

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-26 Downgrade Daiwa Securities Outperform → Neutral
Oct-10-25 Initiated The Benchmark Company Buy
Jul-18-25 Upgrade Jefferies Hold → Buy
Jun-16-25 Initiated Leerink Partners Market Perform
Oct-08-24 Initiated Oppenheimer Outperform
Sep-19-24 Initiated Piper Sandler Overweight
Jul-30-24 Downgrade Edward Jones Buy → Hold
May-30-24 Initiated Goldman Buy
Jul-21-23 Upgrade Wolfe Research Underperform → Peer Perform
May-30-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-20-23 Reiterated Barclays Overweight
Apr-20-23 Reiterated Bernstein Outperform
Apr-20-23 Reiterated JP Morgan Overweight
Apr-20-23 Reiterated Raymond James Outperform
Apr-20-23 Reiterated UBS Buy
Apr-20-23 Reiterated Wolfe Research Underperform
Mar-29-23 Initiated UBS Buy
Oct-26-22 Initiated Mizuho Neutral
Oct-18-22 Initiated Barclays Overweight
Oct-12-22 Initiated Jefferies Hold
Jul-06-22 Initiated Wolfe Research Underperform
Mar-02-22 Resumed BofA Securities Buy
Jan-27-22 Reiterated Credit Suisse Outperform
Jan-27-22 Reiterated Morgan Stanley Overweight
Jan-27-22 Reiterated Raymond James Outperform
Jan-27-22 Reiterated UBS Buy
Dec-10-21 Initiated RBC Capital Mkts Outperform
Oct-27-21 Upgrade Atlantic Equities Neutral → Overweight
Oct-14-21 Initiated Redburn Neutral
May-25-21 Initiated Barclays Overweight
Apr-15-21 Initiated Atlantic Equities Neutral
Jan-28-21 Upgrade BTIG Research Neutral → Buy
Sep-11-20 Initiated Wolfe Research Outperform
Jun-01-20 Downgrade Goldman Neutral → Sell
Mar-05-20 Initiated Citigroup Buy
Feb-13-20 Initiated Goldman Neutral
Feb-06-20 Resumed BTIG Research Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Jun-13-19 Reiterated BofA/Merrill Buy
Feb-07-19 Reiterated BofA/Merrill Buy
Jan-02-19 Downgrade Citigroup Neutral → Sell
Nov-30-18 Upgrade Goldman Neutral → Buy
Oct-16-18 Initiated Barclays Overweight
Jun-27-18 Initiated Bernstein Outperform
Jan-30-18 Reiterated Citigroup Neutral
Jan-25-18 Reiterated Stifel Buy
Jan-25-18 Upgrade William Blair Mkt Perform → Outperform
Jan-03-18 Initiated Evercore ISI Outperform
Jan-02-18 Upgrade JP Morgan Neutral → Overweight
Jan-02-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-19-17 Reiterated RBC Capital Mkts Outperform
Oct-19-17 Reiterated Stifel Buy
View All

Abbott Laboratories Stock (ABT) Latest News

pulisher
10:30 AM

Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain? - Yahoo Finance

10:30 AM
pulisher
06:56 AM

Abbott’s dual ablation catheter lands FDA approval - Yahoo Finance

06:56 AM
pulisher
06:02 AM

Abbott Laboratories stock gains after FDA approval and strong guidance - AD HOC NEWS

06:02 AM
pulisher
Sep 08, 2026

Abbott Laboratories stock heads into the open after a modest loss - AD HOC NEWS

Sep 08, 2026
pulisher
Sep 08, 2026

Here's Why Abbott (ABT) Fell More Than Broader Market - Yahoo Finance

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch

Sep 08, 2026
pulisher
Sep 08, 2026

1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond - The Motley Fool

Sep 08, 2026
pulisher
Sep 08, 2026

FDA approves new Abbott catheter capable of PFA and radiofrequency ablation - Cardiovascular Business

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott wins FDA approval for dual-energy ablation catheter - MedTech Dive

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott receives FDA approval for AFib ablation catheter - grafa.com

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott Laboratories (ABT) Won FDA Approval For Its TactiFlex Duo Catheter - simplywall.st

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott scores another win at UPC with SiBio preliminary injunction - IAM Patent

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott receives FDA approval for dual-energy heart ablation catheter By Investing.com - Investing.com Canada

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott wins FDA nod for cardiac ablation catheter (ABT:NYSE) - Seeking Alpha

Sep 08, 2026
pulisher
Sep 08, 2026

The FDA Clears an Abbott Product - marketscreener.com

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms - PR Newswire

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott Laboratories stock holds firm after July earnings - AD HOC NEWS

Sep 08, 2026
pulisher
Sep 07, 2026

Abbott Laboratories (NYSE:ABT): Can Heart Research Lift Its Next Move? - Kalkine Media

Sep 07, 2026
pulisher
Sep 07, 2026

Abbott Blocks Rival's Glucose Monitor Sales In Europe - Law360

Sep 07, 2026
pulisher
Sep 07, 2026

Abbott Laboratories stock holds valuation premium amid steady earnings - AD HOC NEWS

Sep 07, 2026
pulisher
Sep 07, 2026

Abbott Laboratories (ABT) Stock Analysis: Analyst Consensus Reveals a 10.96% Upside Potential - DirectorsTalk Interviews

Sep 07, 2026
pulisher
Sep 06, 2026

Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets - simplywall.st

Sep 06, 2026
pulisher
Sep 06, 2026

Abbott Laboratories stock holds near $108 after strong Q2 - AD HOC NEWS

Sep 06, 2026
pulisher
Sep 06, 2026

Abbott Laboratories Profile: Recipients - OpenSecrets

Sep 06, 2026
pulisher
Sep 05, 2026

Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript - Fortune

Sep 05, 2026
pulisher
Sep 05, 2026

How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story - simplywall.st

Sep 05, 2026
pulisher
Sep 04, 2026

Abbott CFO Philip P. Boudreau Retains 70,784 Shares After Forfeiting 388 Shares at $110.36 Each - Kalkine Media

Sep 04, 2026
pulisher
Sep 04, 2026

Ferguson Wellman Capital Management Inc. Sells 136,385 Shares of Abbott Laboratories $ABT - InsuranceNewsNet

Sep 04, 2026
pulisher
Sep 04, 2026

Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.

Sep 04, 2026
pulisher
Sep 04, 2026

US companies face rise in cyber attacks - Reuters

Sep 04, 2026
pulisher
Sep 03, 2026

Abbott Laboratories CFO Philip P. Boudreau Reports Sale of 388 Shares at $110.36 in SEC Form 4 Filing - Kalkine Media

Sep 03, 2026
pulisher
Sep 03, 2026

Abbott Laboratories VP John A. McCoy Jr. Reports Share Sales on September 1-2, 2026 - Kalkine Media

Sep 03, 2026
pulisher
Sep 03, 2026

Abbott Laboratories (ABT) CFO reports small tax-related share disposal - Stock Titan

Sep 03, 2026
pulisher
Sep 03, 2026

Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch

Sep 03, 2026
pulisher
Sep 03, 2026

Abbott Laboratories stock gains support from fresh earnings and guidance - AD HOC NEWS

Sep 03, 2026
pulisher
Sep 02, 2026

Abbott ablation device effective at 1 year in complex cases - MedTech Dive

Sep 02, 2026
pulisher
Sep 02, 2026

Small Abbott (NYSE: ABT) insider sale from vested stock award - Stock Titan

Sep 02, 2026
pulisher
Sep 02, 2026

Abbott Laboratories stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Sep 02, 2026
pulisher
Sep 01, 2026

Abbott settlement and Kendamil case add to formula industry scrutiny - FoodNavigator.com

Sep 01, 2026
pulisher
Sep 01, 2026

Abbott Introduces America’s First Liquid Baby Formula With Whole Milk - Yahoo Finance

Sep 01, 2026
pulisher
Aug 31, 2026

Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector? - Barchart.com

Aug 31, 2026
pulisher
Aug 31, 2026

Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch

Aug 31, 2026
pulisher
Aug 31, 2026

How Abbott Labs Is Embracing RFK Jr.'s Make America Healthy Again Movement - Investor's Business Daily

Aug 31, 2026
pulisher
Aug 31, 2026

Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends - 24/7 Wall St.

Aug 31, 2026
pulisher
Aug 31, 2026

Abbott Laboratories Introduces Similac 360 Total Care Made With Whole Milk in US - marketscreener.com

Aug 31, 2026
pulisher
Aug 31, 2026

No mixing: Similac's whole-milk formula launches at powder-like prices - Stock Titan

Aug 31, 2026
pulisher
Aug 31, 2026

Abbott Laboratories (ABT) Stock Analysis: A Healthy Outlook With A 6.87% Upside - DirectorsTalk Interviews

Aug 31, 2026
pulisher
Aug 30, 2026

Abbott Laboratories (ABT) Could Be 6% Below Fair Value Following Libre Duo FDA Approval - simplywall.st

Aug 30, 2026
pulisher
Aug 28, 2026

Abbott wins CE mark for new LAA closure device - medtechdive.com

Aug 28, 2026
pulisher
Aug 27, 2026

Abbott Laboratories agrees to $670M settlement over premature infant formula claims - Top Class Actions

Aug 27, 2026
pulisher
Aug 27, 2026

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up? - 24/7 Wall St.

Aug 27, 2026

Abbott Laboratories Stock (ABT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
MDT MDT
$92.41
price up icon 0.02%
SYK SYK
$272.57
price down icon 1.77%
BSX BSX
$45.17
price up icon 0.33%
EW EW
$86.17
price down icon 0.71%
$84.20
price down icon 0.55%
Cap:     |  Volume (24h):